TNXP Stock Price, Tonix Pharmaceuticals Holding Quote, Chart

Market Summary

USD0.20+0.02

Delayed

11.11%

TNXP Stock Price

View Fullscreen

TNXP RSI Chart

TNXP Valuation

Market Cap

19.1M

Price/Earnings (Trailing)

-0.19

Price/Sales (Trailing)

2.46

Price/Free Cashflow

-0.21

TNXP Price/Sales (Trailing)

TNXP Profitability

Operating Margin

17.60%

Return on Equity

-91.17%

Return on Assets

-72.85%

Free Cashflow Yield

-475.55%

TNXP Fundamentals

TNXP Revenue

Revenue (TTM)

7.8M

Rev. Growth (Yr)

-6.68%

Rev. Growth (Qtr)

-34.32%

TNXP Earnings

Earnings (TTM)

-98.6M

Earnings Growth (Yr)

54.74%

Earnings Growth (Qtr)

45.32%

Breaking Down TNXP Revenue

Last 7 days

17.7%

Last 30 days

25%

Last 90 days

-47.4%

Trailing 12 Months

-89.2%

How does TNXP drawdown profile look like?

TNXP Financial Health

Current Ratio

1.47

Debt/Equity

0.06

Debt/Cashflow

-14.07

TNXP Investor Care

Shares Dilution (1Y)

823.99%

Diluted EPS (TTM)

-3.96

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q3	Q4
2024	0	0	0
2023	3.9M	5.8M	7.8M
2022	0	0	1.9M
2011	0	5.2K	0
2010	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Tonix Pharmaceuticals Holding Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jun 29, 2022	lederman seth	bought	34,200	1.71	20,000	chief executive officer
Mar 25, 2022	lederman seth	bought	24,500	0.245	100,000	chief executive officer
Sep 28, 2021	lederman seth	bought	7,320	0.61	12,000	chief executive officer
Jun 30, 2021	saenger bradley	acquired	10,583	0.58	18,248	chief financial officer
Jun 30, 2021	sullivan gregory m	acquired	21,167	0.58	36,496	chief medical officer
May 25, 2021	goodman daniel wintner	bought	5,600	1.12	5,000	-
Mar 24, 2021	lederman seth	bought	22,087	1.32	16,733	chief executive officer
Jan 07, 2021	sullivan gregory m	acquired	21,074	0.51	41,322	chief medical officer
Dec 30, 2020	lederman seth	bought	23,800	0.68	35,000	chief executive officer
Aug 31, 2020	treco james	bought	4,895	0.89	5,500	-

Which funds bought or sold TNXP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	First Western Trust Bank	unchanged	-	-2,239	1,920	-%
May 16, 2024	JANE STREET GROUP, LLC	new	-	2,553	2,553	-%
May 15, 2024	STATE STREET CORP	unchanged	-	-6,771	5,805	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-76.92	-15.00	1.00	-%
May 15, 2024	Federation des caisses Desjardins du Quebec	new	-	10.00	10.00	-%
May 15, 2024	Beaird Harris Wealth Management, LLC	sold off	-100	-6.00	-	-%
May 15, 2024	Altium Capital Management LP	sold off	-100	-217,630	-	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	reduced	-87.03	-1,428,360	90,954	-%
May 15, 2024	SABBY MANAGEMENT, LLC	added	58.16	-336,894,000	910,649,000	0.52%
May 15, 2024	Tower Research Capital LLC (TRC)	new	-	6,400	6,400	-%

Are Funds Buying or Selling TNXP?

Are funds buying TNXP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TNXP

No. of Funds

Unveiling Tonix Pharmaceuticals Holding Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	6.71%	3,770,000	SC 13G
Feb 14, 2024	alyeska investment group, l.p.	9.99%	5,855,597	SC 13G
Feb 14, 2024	tang capital partners lp	0.0%	0	SC 13G/A
Jan 11, 2024	empery asset management, lp	9.99%	2,313,680	SC 13G
Jan 03, 2024	sabby management, llc	9.99%	5,205,348	SC 13G
Feb 14, 2023	tang capital partners lp	7.4%	4,500,419	SC 13G/A
Dec 27, 2022	tang capital partners lp	7.4%	4,280,916	SC 13G
Jul 08, 2022	blackrock inc.	1.1%	341,736	SC 13G/A
Feb 04, 2022	blackrock inc.	6.2%	30,631,558	SC 13G
Feb 16, 2021	cvi investments, inc.	-	111,250	SC 13G/A

Recent SEC filings of Tonix Pharmaceuticals Holding Corp

View All Filings

Date Filed	Form Type	Document
May 13, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
Apr 15, 2024	ARS	ARS
Apr 15, 2024	DEF 14A	DEF 14A
Apr 05, 2024	PRE 14A	PRE 14A
Apr 01, 2024	10-K	Annual Report
Apr 01, 2024	8-K	Current Report
Mar 29, 2024	424B5	Prospectus Filed
Mar 29, 2024	8-K	Current Report
Mar 25, 2024	8-K	Current Report

Peers (Alternatives to Tonix Pharmaceuticals Holding Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Tonix Pharmaceuticals Holding Corp News

Latest updates

Tonix Pharmaceuticals Holding Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)									(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q1	2022Q4	2011Q3	2011Q2	2010Q3	2010Q2
Revenue	-34.3%	2,482	3,779	3,989	2,660	1,330	1.00	1.00	1.00	2.00
Cost Of Revenue	-29.9%	1,660	2,367	2,374	-	-	-	-	-	-
Costs and Expenses	-23.4%	23,833	31,108	32,136	33,902	32,728	-	-	-	-
Operating Expenses	-	-	-	-	-	-	1,014	356	-	-
S&GA Expenses	-19.9%	9,310	11,622	8,712	7,391	8,054	-	-	-	-
R&D Expenses	-24.9%	12,863	17,119	21,050	26,511	24,674	-	-	-	-
Interest Expenses	-	-	-	-	-	-	8*	22*	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-
Net Income	45.3%	-14,939	-27,322	-27,975	-33,005	-31,680	-	-	-	-
Net Income Margin	15.5%	-12.69*	-15.02*	-20.77*	-30.05*	-56.64*	-	-	-	-
Free Cashflow	22.4%	-17,683	-22,778	-25,198	-36,710	-26,972	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-12.4%	135	154	139	160	179	226	243	276	224	241	215	189	184	98.00	68.00	58.00	34.00	15.00	12.00	15.00	20.00
Current Assets	-37.0%	30.00	48.00	31.00	51.00	84.00	131	151	192	153	189	195	177	173	88.00	62.00	58.00	33.00	14.00	12.00	14.00	19.00
Cash Equivalents	-68.1%	8.00	25.00	7.00	26.00	72.00	120	140	145	140	179	183	166	164	77.00	56.00	55.00	31.00	11.00	10.00	12.00	17.00
Inventory	-9.4%	12.00	14.00	13.00	14.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-1.0%	93.00	94.00	95.00	96.00	94.00	94.00	90.00	83.00	70.00	51.00	18.00	10.00	9.00	9.00	4.00	0.00	0.00	0.00	0.00	0.00	0.00
Goodwill	0%	1.00	1.00	1.00	1.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	-44.4%	27.00	49.00	18.00	19.00	14.00	19.00	14.00	16.00	16.00	22.00	13.00	9.00	7.00	11.00	5.00	5.00	3.00	5.00	2.00	2.00	2.00
Current Liabilities	8.4%	20.00	19.00	18.00	18.00	13.00	18.00	13.00	16.00	15.00	22.00	12.00	8.00	6.00	10.00	4.00	5.00	3.00	5.00	2.00	2.00	2.00
Long Term Debt	-6.1%	6.00	7.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Current	20.0%	3.00	2.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	7.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	2.5%	108	106	121	140	165	207	229	228	208	219	202	180	177	88.00	63.00	54.00	31.00	9.00	10.00	13.00	18.00
Retained Earnings	-2.5%	-615	-600	-573	-545	-516	-470	-438	-409	-386	-359	-330	-311	-288	-267	-250	-238	-224	-217	-208	-200	-194
Additional Paid-In Capital	2.5%	724	706	694	686	683	677	667	638	594	579	532	492	465	355	313	292	256	227	218	213	213
Shares Outstanding	44.1%	84.00	59.00	18.00	11.00	10.00	12.00	7.00	4.00	3.00	3.00	2.00	2.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	17.00	-	-	-	50.00	-	-	-	384	-	-	-	63,914	-	-	-	7,273	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	21.3%	-17,575	-22,340	-23,385	-23,367	-32,911	-22,301	-23,535	-21,171	-31,046	-22,445	-12,946	-19,108	-21,058	-13,914	-15,285	-10,041	-9,326	-6,683	-6,645	-4,713	-8,642
Share Based Compensation	-17.0%	1,692	2,038	2,079	2,364	2,794	2,716	2,765	2,813	2,620	2,296	2,302	2,089	1,212	871	912	733	360	359	362	431	305
Cashflow From Investing	74.9%	-108	-431	-821	-24,019	-3,799	-4,671	-8,820	-14,439	-20,217	-25,622	-7,751	-1,429	-505	-4,534	-4,016	-	-	-5.00	-2.00	-3.00	-7.00
Cashflow From Financing	-100.5%	-212	40,714	6,274	1,029	-11,500	7,229	-4,625	72,177	13,063	43,767	37,961	22,049	108,710	39,859	20,069	34,420	28,757	7,914	4,515	417	73.00
Buy Backs	-	-	-	-	-	13,965	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TNXP Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
REVENUES:
Product revenue, net	$ 2,482
COSTS AND EXPENSES:
Cost of sales	1,660
Research and development	12,863	26,511
General and administrative	9,310	7,391
Total operating expenses	23,833	33,902
Operating loss	(21,351)	(33,902)
Gain on change in fair value of warrant liabilities	7,005
Other (expense) income, net	(593)	897
Net loss available to common stockholders	$ (14,939)	$ (33,005)
Net loss per common share, basic	$ (0.18)	$ (3.21)
Net loss per common share, diluted	$ (0.18)	$ (3.21)
Weighted average common shares outstanding, basic	80,879,108	10,268,500
Weighted average common shares outstanding, diluted	80,879,108	10,268,500

TNXP Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 7,049	$ 24,948
Inventory, net	12,351	13,639
Prepaid expenses and other current assets	10,698	9,181
Total current assets	30,098	47,768
Property and equipment, net	93,058	94,028
Intangible assets, net	9,505	9,743
Goodwill	965	965
Operating lease right-to-use assets	757	824
Other non-current assets	960	1,129
Total assets	135,343	154,457
Current liabilities:
Accounts payable	6,649	3,782
Accrued expenses and other current liabilities	10,733	12,482
Term loan payable, short term	2,820	2,350
Lease liability, short term	277	270
Total current liabilities	20,479	18,884

Term loan payable, long term	6,158	6,561
Lease liability, long term	563	632
Total liabilities	27,200	48,932
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized, 0 shares designated as of both March 31, 2024, and December 31, 2023; 0 shares issued and outstanding - as of both March 31, 2024 and December 31, 2023
Common stock, $0.001 par value; 1,000,000,000 shares authorized; 73,724,196 and 58,614,593 shares issued and outstanding as of March 31, 2024, and December 31, 2023, respectively and 66,359 shares to be issued as of December 31, 2023	74	59
Additional paid in capital	723,906	706,356
Accumulated deficit	(615,597)	(600,658)
Accumulated other comprehensive loss	(240)	(232)
Total stockholders’ equity	108,143	105,525
Total liabilities and stockholders’ equity	135,343	154,457
Series C Warrant [Member]

Warrant liabilities		14,595
Series D Warrant [Member]

Warrant liabilities		$ 8,260

About Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, develops therapeutics and vaccines to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed to treat autoimmune conditions. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; and TNX-102 SL, a CNS product candidate to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a recombinant protein enzyme to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

CEO	Dr. Seth Lederman M.D.
WEBSITE	tonixpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	117

Tonix Pharmaceuticals Holding Corp Frequently Asked Questions

What is the ticker symbol for Tonix Pharmaceuticals Holding Corp? What does TNXP stand for in stocks?

TNXP is the stock ticker symbol of Tonix Pharmaceuticals Holding Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Tonix Pharmaceuticals Holding Corp (TNXP)?

As of Fri May 17 2024, market cap of Tonix Pharmaceuticals Holding Corp is 19.11 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TNXP stock?

You can check TNXP's fair value in chart for subscribers.

What is the fair value of TNXP stock?

You can check TNXP's fair value in chart for subscribers. The fair value of Tonix Pharmaceuticals Holding Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Tonix Pharmaceuticals Holding Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TNXP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Tonix Pharmaceuticals Holding Corp a good stock to buy?

The fair value guage provides a quick view whether TNXP is over valued or under valued. Whether Tonix Pharmaceuticals Holding Corp is cheap or expensive depends on the assumptions which impact Tonix Pharmaceuticals Holding Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TNXP.

What is Tonix Pharmaceuticals Holding Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, TNXP's PE ratio (Price to Earnings) is -0.19 and Price to Sales (PS) ratio is 2.46. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TNXP PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Tonix Pharmaceuticals Holding Corp's stock?

In the past 10 years, Tonix Pharmaceuticals Holding Corp has provided -0.797 (multiply by 100 for percentage) rate of return.